Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 19 years or older
- People who have been diagnosed with unstable angina (chest pain at rest or with minimal activity), or a heart attack, including both NSTEMI and STEMI types
- People with coronary artery disease where at least one artery is blocked by more than 70%, the affected artery is a certain size, and a stent has been identified as the appropriate treatment
- People whose blockage(s) are suitable to be treated with a specific stent called the Synergy stent system
- People (or their legal guardian) who are willing to agree to the study procedures, attend follow-up appointments, and sign a written consent form that has been approved by the relevant ethics committee
Who may not be able to join:
- People aged over 90 years
- People with a known allergy or sensitivity to the materials used in the stent device — including everolimus, certain polymers, cobalt, chromium, nickel, platinum, tungsten, or related substances — where the allergy cannot be managed with prior medication
- People with a severe allergy to the contrast dye used in heart imaging, or to blood-thinning medications (including aspirin and P2Y12 inhibitors such as clopidogrel), where the allergy cannot be managed with prior medication
- People who have a planned non-heart surgery scheduled within 6 months after the procedure that would require stopping blood-thinning medications
- People currently in cardiogenic shock (when the heart is suddenly unable to pump enough blood to the body)
- People whose artery blockage is a re-narrowing of a previously treated artery (restenosis)
- People with severely reduced heart pumping function (confirm with trial site)
- People with an active cancer diagnosis that is not currently in remission
- People with serious non-heart-related health conditions where life expectancy is less than 1 year
- People who are currently taking part in another clinical trial for a drug or medical device that has not yet completed its main follow-up period
- People who, in the investigator's judgment, belong to a vulnerable population, or who are unable to read or write
- People where there is concern they may not be able to follow the study procedures or attend follow-up appointments — for example, due to alcohol or drug dependency
- People who are pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Suk Min Seo, MD, PhD, The Catholic University of Korea Eunpyeong St. Mary's Hospital
Phone: 82+010-9090-8491
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Target Vessel Failure (TVF)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.